{"filing":{"accession_number":"0001193125-26-400087","cik":"0001585608","ticker":"JAGX","company_name":"Jaguar Health, Inc.","form":"8-K","filing_date":"2026-09-24","report_date":"2026-09-23","primary_document":"d161376d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526400087/d161376d8k.htm"},"events":[{"id":34694,"run_id":31939,"accession_number":"0001193125-26-400087","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"On September 23, 2026, Jaguar Health completed a debt-for-equity exchange, issuing 547,898 shares of common stock to reduce the outstanding balance of a secured promissory note by $5.05 million. This restructuring materially affects the company's capital structure and shareholder equity.","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-09-24","form":"8-K","submitted_at":null,"items":[{"id":38510,"accession_number":"0001193125-26-400087","item_number":"1.01","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.45,"reasoning":"The filing discloses a debt-for-equity exchange on September 23, 2026, where Jaguar Health exchanged 547,898 shares of common stock for a $5.05 million reduction in the outstanding balance of a $10.81 million secured promissory note. While this is technically a modification of existing debt rather than issuance of new debt, and involves a dilutive equity issuance, the principal disclosed action centers on restructuring the 2025 Note obligation. The event is material because it reduces debt by over $5 million and dilutes shareholders by ~548k shares, affecting both capital structure and equity holders.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-24T10:05:40.719140+00:00","company_name":"","ticker":null,"filing_date":""},{"id":38511,"accession_number":"0001193125-26-400087","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Item 3.02 discloses unregistered issuance of equity securities (the \"2025 Note Exchange Shares\") relying on Section 3(a)(9) of the Securities Act. This is a classic dilutive issuance — an unregistered sale of equity securities. The reference to Item 1.01 suggests this is part of a larger transaction (likely a debt-for-equity exchange), which is material to investors assessing capital structure and ownership dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-24T10:05:40.719140+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":34695,"run_id":31939,"accession_number":"0001193125-26-400087","anchor_item_number":"8.01","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.75,"summary":"The filing reports the number of outstanding shares of common stock as of September 23, 2026, a routine administrative disclosure of capitalization data.","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-09-24","form":"8-K","submitted_at":null,"items":[{"id":38512,"accession_number":"0001193125-26-400087","item_number":"8.01","item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.75,"reasoning":"This disclosure reports the number of outstanding shares of Common Stock as of September 23, 2026. It is a routine administrative disclosure of capitalization data, typically included in 8-K filings for informational purposes. While share count is factual information, this bare statement of shares outstanding—without context of a capital event, dilution, or change—does not constitute a material event affecting investor assessment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-24T10:05:40.719140+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38510,"accession_number":"0001193125-26-400087","item_number":"1.01","item_title":null,"event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.45,"reasoning":"The filing discloses a debt-for-equity exchange on September 23, 2026, where Jaguar Health exchanged 547,898 shares of common stock for a $5.05 million reduction in the outstanding balance of a $10.81 million secured promissory note. While this is technically a modification of existing debt rather than issuance of new debt, and involves a dilutive equity issuance, the principal disclosed action centers on restructuring the 2025 Note obligation. The event is material because it reduces debt by over $5 million and dilutes shareholders by ~548k shares, affecting both capital structure and equity holders.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-24T10:05:40.719140+00:00","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-09-24"},{"id":38511,"accession_number":"0001193125-26-400087","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Item 3.02 discloses unregistered issuance of equity securities (the \"2025 Note Exchange Shares\") relying on Section 3(a)(9) of the Securities Act. This is a classic dilutive issuance — an unregistered sale of equity securities. The reference to Item 1.01 suggests this is part of a larger transaction (likely a debt-for-equity exchange), which is material to investors assessing capital structure and ownership dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-24T10:05:40.719140+00:00","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-09-24"},{"id":38512,"accession_number":"0001193125-26-400087","item_number":"8.01","item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.75,"reasoning":"This disclosure reports the number of outstanding shares of Common Stock as of September 23, 2026. It is a routine administrative disclosure of capitalization data, typically included in 8-K filings for informational purposes. While share count is factual information, this bare statement of shares outstanding—without context of a capital event, dilution, or change—does not constitute a material event affecting investor assessment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-24T10:05:40.719140+00:00","company_name":"Jaguar Health, Inc.","ticker":"JAGX","filing_date":"2026-09-24"}]}